119 related articles for article (PubMed ID: 19183560)
1. A mathematical model of doxorubicin penetration through multicellular layers.
Evans CJ; Phillips RM; Jones PF; Loadman PM; Sleeman BD; Twelves CJ; Smye SW
J Theor Biol; 2009 Apr; 257(4):598-608. PubMed ID: 19183560
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of P-glycoprotein function by XR9576 in a solid tumour model can restore anticancer drug efficacy.
Walker J; Martin C; Callaghan R
Eur J Cancer; 2004 Mar; 40(4):594-605. PubMed ID: 14962729
[TBL] [Abstract][Full Text] [Related]
3. A mechanistic study of enhanced doxorubicin uptake and retention in multidrug resistant breast cancer cells using a polymer-lipid hybrid nanoparticle system.
Wong HL; Bendayan R; Rauth AM; Xue HY; Babakhanian K; Wu XY
J Pharmacol Exp Ther; 2006 Jun; 317(3):1372-81. PubMed ID: 16547167
[TBL] [Abstract][Full Text] [Related]
4. Nanoparticle-mediated combination chemotherapy and photodynamic therapy overcomes tumor drug resistance in vitro.
Khdair A; Handa H; Mao G; Panyam J
Eur J Pharm Biopharm; 2009 Feb; 71(2):214-22. PubMed ID: 18796331
[TBL] [Abstract][Full Text] [Related]
5. The penetration of anticancer drugs through tumor tissue as a function of cellular adhesion and packing density of tumor cells.
Grantab R; Sivananthan S; Tannock IF
Cancer Res; 2006 Jan; 66(2):1033-9. PubMed ID: 16424039
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of a novel in vitro assay for assessing drug penetration into avascular regions of tumours.
Phillips RM; Loadman PM; Cronin BP
Br J Cancer; 1998 Jun; 77(12):2112-9. PubMed ID: 9649122
[TBL] [Abstract][Full Text] [Related]
7. The effect of fatty acids and analogues upon intracellular levels of doxorubicin in cells displaying P-glycoprotein mediated multidrug resistance.
Abulrob AN; Mason M; Bryce R; Gumbleton M
J Drug Target; 2000; 8(4):247-56. PubMed ID: 11144235
[TBL] [Abstract][Full Text] [Related]
8. Reversal of P-gp mediated multidrug resistance in-vitro and in-vivo by FG020318.
Chen LM; Liang YJ; Ruan JW; Ding Y; Wang XW; Shi Z; Gu LQ; Yang XP; Fu LW
J Pharm Pharmacol; 2004 Aug; 56(8):1061-6. PubMed ID: 15285852
[TBL] [Abstract][Full Text] [Related]
9. Alternation of adriamycin penetration kinetics in MCF-7 cells from 2D to 3D culture based on P-gp expression through the Chk2/p53/NF-κB pathway.
Lu M; Zhou F; Hao K; Liu J; Chen Q; Ni P; Zhou H; Wang G; Zhang J
Biochem Pharmacol; 2015 Jan; 93(2):210-20. PubMed ID: 25478729
[TBL] [Abstract][Full Text] [Related]
10. Levels of multidrug resistance (MDR1) P-glycoprotein expression by human breast cancer correlate with in vitro resistance to taxol and doxorubicin.
Mechetner E; Kyshtoobayeva A; Zonis S; Kim H; Stroup R; Garcia R; Parker RJ; Fruehauf JP
Clin Cancer Res; 1998 Feb; 4(2):389-98. PubMed ID: 9516927
[TBL] [Abstract][Full Text] [Related]
11. Nitric oxide attenuates resistance to doxorubicin in three-dimensional aggregates of human breast carcinoma cells.
Muir CP; Adams MA; Graham CH
Breast Cancer Res Treat; 2006 Mar; 96(2):169-76. PubMed ID: 16331349
[TBL] [Abstract][Full Text] [Related]
12. Nuclear immunolocalization of P-glycoprotein in multidrug-resistant cell lines showing similar mechanisms of doxorubicin distribution.
Baldini N; Scotlandi K; Serra M; Shikita T; Zini N; Ognibene A; Santi S; Ferracini R; Maraldi NM
Eur J Cell Biol; 1995 Nov; 68(3):226-39. PubMed ID: 8603675
[TBL] [Abstract][Full Text] [Related]
13. Penetration of paclitaxel and 5-fluorouracil in multicellular layers of human colorectal cancer cells.
Choi MS; Kim SH; Kuh HJ
Oncol Rep; 2011 Mar; 25(3):863-70. PubMed ID: 21225235
[TBL] [Abstract][Full Text] [Related]
14. Reversal of multidrug resistance by two nordihydroguaiaretic acid derivatives, M4N and maltose-M3N, and their use in combination with doxorubicin or paclitaxel.
Chang CC; Liang YC; Klutz A; Hsu CI; Lin CF; Mold DE; Chou TC; Lee YC; Huang RC
Cancer Chemother Pharmacol; 2006 Nov; 58(5):640-53. PubMed ID: 16544145
[TBL] [Abstract][Full Text] [Related]
15. Modulation of P-glycoprotein-mediated multidrug resistance by acceleration of passive drug permeation across the plasma membrane.
Regev R; Katzir H; Yeheskely-Hayon D; Eytan GD
FEBS J; 2007 Dec; 274(23):6204-14. PubMed ID: 17986257
[TBL] [Abstract][Full Text] [Related]
16. Accelerator mass spectrometry allows for cellular quantification of doxorubicin at femtomolar concentrations.
DeGregorio MW; Dingley KH; Wurz GT; Ubick E; Turteltaub KW
Cancer Chemother Pharmacol; 2006 Feb; 57(3):335-42. PubMed ID: 16047147
[TBL] [Abstract][Full Text] [Related]
17. Severe combined immunodeficiency (SCID) mouse modeling of P-glycoprotein chemosensitization in multidrug-resistant human myeloma xenografts.
Bellamy WT; Odeleye A; Huizenga E; Dalton WS; Weinstein RS; Grogan TM
Clin Cancer Res; 1995 Dec; 1(12):1563-70. PubMed ID: 9815957
[TBL] [Abstract][Full Text] [Related]
18. REIC/Dkk-3 overexpression downregulates P-glycoprotein in multidrug-resistant MCF7/ADR cells and induces apoptosis in breast cancer.
Kawasaki K; Watanabe M; Sakaguchi M; Ogasawara Y; Ochiai K; Nasu Y; Doihara H; Kashiwakura Y; Huh NH; Kumon H; Date H
Cancer Gene Ther; 2009 Jan; 16(1):65-72. PubMed ID: 18654608
[TBL] [Abstract][Full Text] [Related]
19. Differential changes in purine nucleotides after Doxorubicin treatment of human cancer cells in vitro.
Walenta S; Feigk B; Wachsmuth I; Dunkern T; Degani H; Mueller-Klieser W
Int J Oncol; 2002 Aug; 21(2):289-96. PubMed ID: 12118323
[TBL] [Abstract][Full Text] [Related]
20. Cell-specific modulation of drug resistance in acute myeloid leukemic blasts by diphtheria fusion toxin, DT388-GMCSF.
Frankel AE; Hall PD; McLain C; Safa AR; Tagge EP; Kreitman RJ
Bioconjug Chem; 1998; 9(4):490-6. PubMed ID: 9667951
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
